ASX Healthcare Stocks to Watch in September 2026: Sigma Healthcare (ASX:SIG), Neuren Pharmaceuticals (ASX:NEU) and Mesoblast (ASX:MSB)

Sonal Goyal

14 September 2026 08:39 PM AEST

ASX Healthcare Stocks to Watch in September 2026: Sigma Healthcare (ASX:SIG), Neuren Pharmaceuticals (ASX:NEU) and Mesoblast (ASX:MSB)

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Sigma Healthcare (ASX:SIG), Neuren Pharmaceuticals (ASX:NEU) and Mesoblast (ASX:MSB) operate across pharmacy distribution and retail, rare-disease pharmaceuticals and cellular medicines. Their 2026 company updates covered financial performance, network expansion, Royalty income, regulatory activity, product commercialisation and clinical development.

Sigma Healthcare (ASX:SIG)

Sigma Healthcare operates pharmaceutical wholesale distribution, Franchise services and pharmacy retail activities. Its network includes Chemist Warehouse and My Chemist, with operations across Australia and international markets.

For FY26, Sigma reported Revenue of AUD 10.8 billion, an increase of 15.5%. Normalised EBIT reached AUD 1.09 billion, representing growth of 20.6%, while the normalised EBIT Margin was 10.1%. Normalised net profit after tax was AUD 732.3 million, up 22.3%.

The Australian segment recorded revenue growth of 14.9%, while international segment EBIT increased 91.3% to AUD 55.8 million. Sigma also reported AUD 32.6 million of integration synergies during FY26 and maintained its target of AUD 100 million in annual synergies by FY29. Net Debt was AUD 663 million, with debt representing 0.57 times normalised EBITDA.

Sigma Healthcare (ASX:SIG) also continued network expansion during FY26. Company disclosures reported further development of its domestic and international pharmacy operations alongside ongoing integration activities.

Neuren Pharmaceuticals (ASX:NEU)

Neuren Pharmaceuticals develops treatments for serious neurological conditions. Acadia Pharmaceuticals is Neuren's exclusive worldwide licensee for trofinetide, which is marketed as DAYBUE for Rett syndrome. Neuren also owns the NNZ-2591 development program.

In the second quarter of 2026, DAYBUE net sales reached USD 125 million, an increase of 24% from the first quarter of 2026. Neuren earned Q2 royalty income of USD 12.9 million. Following the quarter, Acadia increased its full-year 2026 DAYBUE net sales guidance to USD 480 million–USD 510 million, implying anticipated full-year royalty income for Neuren of USD 53 million–USD 56 million.

Neuren Pharmaceuticals (ASX:NEU) continued development of NNZ-2591 during 2026. Its Koala study is evaluating the therapy in Phelan-McDermid syndrome, while the company's development activities remain centred on neurological conditions with limited treatment options.

Mesoblast (ASX:MSB)

Mesoblast develops allogeneic cellular medicines. Its commercial portfolio includes Ryoncil, or remestemcel-L, for paediatric steroid-refractory acute graft-versus-host disease, alongside development programs covering other inflammatory and degenerative conditions.

Mesoblast released its annual financial results and operational update for the year ended 30 June 2026 on 27 August 2026. The company reported approximately USD 120.3 million in total revenue, including approximately USD 115.2 million of Ryoncil net revenue. Gross Profit was approximately USD 103.6 million. The net loss was approximately USD 57.5 million.

Ryoncil's commercial rollout expanded during FY26, with the company increasing the number of treatment centres using the therapy and extending payer coverage in the United States.

Healthcare Operations in 2026

Sigma's FY26 disclosures centred on revenue growth, pharmacy network operations and integration activity. The company reported AUD 10.8 billion of revenue and AUD 1.09 billion of normalised EBIT during the year.

Neuren's 2026 updates included DAYBUE quarterly sales and royalties, European regulatory developments and continuing development of NNZ-2591. DAYBUE generated Q2 2026 net sales of USD 125 million, with Neuren receiving USD 12.9 million in royalties for the quarter.

Mesoblast's FY26 update covered the first full financial year of Ryoncil commercial sales in the United States, together with continued clinical development across its cellular medicine portfolio.

FAQs

Q: What did Sigma Healthcare report for FY26?

A: Sigma reported FY26 revenue of AUD 10.8 billion, normalised EBIT of AUD 1.09 billion and normalised net profit after tax of AUD 732.3 million.

Q: What did Neuren report for DAYBUE in Q2 2026?

A: DAYBUE recorded Q2 net sales of USD 125 million, while Neuren earned USD 12.9 million in royalty income for the quarter.

Q: What did Mesoblast report for FY26?

A: Mesoblast reported approximately USD 120.3 million in total revenue, including approximately USD 115.2 million in Ryoncil net revenue.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.